Amylyx Pharmaceuticals

IPO

Home | Amylyx

Public · Cambridge, United States · Founded 2013 · $197.3M raised

Founded
2013
Business Model
B2B
Website
amylyx.com
Total Funding
$197.3M
Last Round
$5.0M Series AJul 2021
Rounds
4
Type
Public

About

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2013 by Josh Cohen and Justin Klee at Brown University, headquartered in Cambridge, Massachusetts. The company is dedicated to developing novel therapies for diseases with high unmet needs, with a pipeline spanning ALS, Wolfram syndrome, post-bariatric hypoglycemia, and congenital hyperinsulinism. Amylyx completed its IPO on NASDAQ in January 2022 and has advanced multiple investigational therapies through Phase 2 and Phase 3 clinical trials, backed by rigorous science and deep engagement with patient communities.

Summary

Amylyx Pharmaceuticals is a Healthcare company based in Cambridge, United States, founded in 2013. It has raised $197.3M in total across 4 rounds, most recently a $5.0M Series A round in Jul 2021. Investors include Morningside Group, Viking Global and ALS Investment Fund.

Tech & App Stack

8 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CJul 2021
$135.0M

Sign up to see all 4 rounds

Series A through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Amylyx Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/amylyx-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/amylyx-pharmaceuticals" alt="Amylyx Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>